Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, China.
Expert Rev Clin Pharmacol. 2021 Apr;14(4):411-426. doi: 10.1080/17512433.2021.1901575. Epub 2021 Mar 17.
: Procedural sedation (PS) is a humane way to help patients get through painful medical procedures by the administration of sedative drugs combined with analgesics. However, each of the currently used medications has certain shortcomings, urging the search for a new drug. Remimazolam, a novel benzodiazepine, is an ultra-short-acting hypnotic agent invented out of the 'soft drug' development.: This presented review provides an overview of the drugs used in clinical practice for the induction and maintenance of procedural sedation in adults, focusing on the newly investigated benzodiazepine remimazolam. Literature search was conducted using the MEDLINE and ClinicalTrial.gov databases from January 2007 to December 2020.: Based on the reported clinical trials so far, remimazolam has demonstrated its effectiveness and safety with promising properties including rapid onset, short duration of action, predictable and consistent recovery profile, metabolism almost unaffected by liver or renal function, with non or minimal cardiorespiratory depression, and availability with a reversal drug. With marketing approval received recently, remimazolam is expected to have a place in the practice for procedural sedation in the near future if its efficacy and safety are further confirmed by more clinical trials and post-market analyses.
: 程序性镇静（PS）是一种通过给予镇静药物联合镇痛药来帮助患者完成痛苦的医疗程序的人道方法。然而，目前使用的每种药物都有一定的缺点，促使人们寻找新药。咪达唑仑是一种新型苯二氮䓬类药物，是从“软毒品”开发出来的一种超短效催眠剂。
: 本综述介绍了目前用于成人诱导和维持程序镇静的临床实践中使用的药物，重点介绍了新研究的苯二氮䓬类药物咪达唑仑。文献检索使用了 MEDLINE 和 ClinicalTrial.gov 数据库，检索时间为 2007 年 1 月至 2020 年 12 月。
: 根据迄今为止报告的临床试验，咪达唑仑具有起效迅速、作用时间短、恢复预测性和一致性好、代谢几乎不受肝肾功能影响、对心肺功能抑制作用小或无、具有逆转药物等特点，已证明其有效性和安全性。最近获得了营销批准，如果更多的临床试验和上市后分析进一步证实其疗效和安全性，咪达唑仑有望在不久的将来在程序镇静实践中占有一席之地。
